This study aims to predict the potential targets and molecular mechanism of Sargentodoxa cuneata for the treatment of cerebral infarction (CI) based on ultra-performance liquid chromatography-high-resolution mass spectrometry (UPLC-HR-MS),network pharmacology and molecular docking.UPLC-HR-MS was used to conduct a preliminary analysis of the chemical composition of S. cuneata.A total of 20 chemical constituents,including phenylpropanoids,anthraquinones,phenolic acids and triterpenoids were identified in S. cuneata.Based on chemical composition analysis,visual “chemical composition-disease target-biological pathway” network was established through network pharmacology analysis,and a total of 71 potential core targets for the treatment of CI were selected,including PIK3CA,SRC,STAT3 and so on.The enrichment results of the KEGG pathway suggested that the pathway of these key targets is mainly related to HIF-1,ErBb,sphingolipid pathways and so on.The molecular docking of the core targets was further verified,and the results showed that 3,4-dihydroxyphenylethyl alcohol glucoside,cuneataside E and physcion had good affinity with APP,PIK3CA,STAT3 and other targets.In summary,this paper indicates that the components of S. cuneata act on multiple targets,participate in the regulation of multiple pathways to exert the mechanism of treating CI,which provides a basis and reference for further verifying the pharmacodynamic substance and mechanism of S. cuneata for the treatment of CI.